Orthocell (ASX:OCC) said the US rollout of its nerve repair product Remplir is well ahead of schedule, according to a Friday Australian bourse filing.
The company expects Remplir's US revenue from early surgical cases to grow in the second half of the fiscal year, the filing said.
Orthocell's shares were down almost 3% in recent Friday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.